Eiji Sugiyama (E Sugiyama)

Publication Activity (10 Years)

Years Active: 2019-2021
Publications (10 Years): 4

Top Topics

Idiopathic Pulmonary Fibrosis

Interstitial Lung Disease

Systemic Sclerosis

Atopic Dermatitis

Top Venues

Modern rheumatology

The Journal of asthma : official journal of the Association for the Care of Asthma

Clinical and experimental immunology

This page only lists publications with an associated author ORCID identifier.

Publications

Toshihito Otani, Hiroshi Iwamoto, Yusuke Yoshida, Kakuhiro Yamaguchi, Shinjiro Sakamoto, Yasushi Horimasu, Takeshi Masuda, Shintaro Miyamoto, Taku Nakashima, Kazunori Fujitaka, Hironobu Hamada, Shintaro Hirata, Eiji Sugiyama, Noboru Hattori
Dupilumab as an adjunct treatment for a patient with steroid-dependent immunoglobulin G4-related disease complicated by asthma: a case report. The Journal of asthma : official journal of the Association for the Care of Asthma 59 (12) (2021)
Shintaro Hirata, Hiroki Kohno, Hirofumi Watanabe, Tadahiro Tokunaga, Yusuke Yoshida, Tomohiro Sugimoto, Sho Mokuda, Keisuke Oda, Takaki Nojima, Eiji Sugiyama
Tapering and discontinuation of oral glucocorticoids without deterioration of disease status in patients with rheumatoid arthritis under a stable treatment. Modern rheumatology 31 (4) (2021)
Yusuke Yoshida, Tomohiro Sugimoto, Yohei Hosokawa, Harumichi Suma, Hiroki Kobayashi, Michinori Ishitoku, Hiroki Kohno, Tadahiro Tokunaga, Hirofumi Watanabe, Sho Mokuda, Takaki Nojima, Shintaro Hirata, Eiji Sugiyama
C-reactive protein and ground-glass opacity as predictors for intractable interstitial lung disease in patients with systemic sclerosis under cyclophosphamide treatment regardless of concomitant glucocorticoids. Modern rheumatology (2021)
K Oi, T Tokunaga, T Kuranobu, K Yukawa, H Kohno, Y Yoshida, S Mokuda, Shintaro Hirata, Eiji Sugiyama
Tumour necrosis factor α augments the inhibitory effects of CTLA-4-Ig on osteoclast generation from human monocytes via induction of CD80 expression. Clinical and experimental immunology 196 (3) (2019)